Bleeding Disorders

Bleeding disorder is a set of disorders, or disease which normally affect the process of clotting of our blood. This bleeding can be in many cases like during an accident, trauma condition, surgery, injury or a menstrual cycle. These bleeding disorders are not only associated with bloods leaving out from our body, rather it can also be an internal bleeding beneath our skin or brain. These may be hemophilia A and B or Willebrand?s disease for example. Sometimes this disease is also termed as royal disease.

The main symptom of bleeding disorder would be excessive bleeding and prolonged clotting time during normal injuries also. These can also easily identified by frequent nose bleeding, heavy menstrual bleeding and unexplained bruishing.

There are mainly two common type of instant treatment available for bleeding disorder, which is iron supplementation or clotting factor repalacement and blood transfusion. These are the therapeutic aspect, but extended research is in progress in various countries, where this disease has a greater prevalence rate.

We present data collected in HemoRec, an Internet-based platform implemented in 2006 in 15 haemophilia treatment centres in Poland and compare them with the national registry of inherited bleeding disorders established since 1991 at the Institute of Haematology and Blood Transfusion in Warsaw.  Data on 1102 patients registered in HemoRec were analysed and compared with 4294 patients in the national registry (status as at 17.08.2009). The number of patients with severe haemophilia, mild/moderate haemophilia and von Willebrand in HemoRec is 530, 328 and 54 (respectively), compared with 1199, 1167 and 1128 in the national registry. The mean age of all haemophilic patients registered in HemoRec is 26.2 years, compared with 37.3 years in the general Polish male population in 2008. The number of haemophilic patients with inhibitor registered in HemoRec is 102 compared with 155 in the national registry (resulting in a prevalence of 14.9% of all severe haemophilia A and 1.6% of all severe haemophilia B patients).